Change of Adviser

RNS Number : 9998K

OptiBiotix Health PLC

28 September 2016

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Appointment of Broker

OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces that it has appointed finnCap as its sole broker with immediate effect.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information:

OptiBiotix Health plc		www.optibiotix.com
Stephen O'Hara, Chief Executive		Contact via Walbrook below
Cairn Financial Advisers LLP (Nominated Adviser)		Tel: [phone]
Liam Murray / Jo Turner
finnCap (Sole Broker)
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)			Tel: [phone]
Tony Quirke (Corporate Broking)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Anna Dunphy		Mob: [phone]

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

END

 

 

APPLLFLRADIDFIR